Can you take Ranolazine with Tucatinib?
1 drug interaction and 7 additional warnings found for the following 2 drugs:
- ranolazine
- tucatinib
Drug interactions
Major drug interactions
Major:
ranolazine tucatinib
Applies to: ranolazine and tucatinib
Using ranolazine together with tucatinib is not recommended. Combining these medications may significantly increase the blood levels and effects of ranolazine.
High blood levels of ranolazine can occasionally cause an irregular heart rhythm that may be serious.
You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, or fast or pounding heartbeats during treatment with tucatinib.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:
ranolazine Food/Lifestyle
Applies to: ranolazine
You may take ranolazine with or without food, but should try to take it the same way every time.
Grapefruit and grapefruit juice should be avoided if possible. Grapefruit juice can increase the levels of ranolazine in your body.
High blood levels of food can occasionally cause an irregular heart rhythm that may be serious.
You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, or fast or pounding heartbeats during treatment with ranolazine.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
6 potential interactions Applies to: 4 conditions, including Hyperkalemia, Liver Disease, Long QT Syndrome, and Renal Dysfunction.
Hyperkalemia
Moderate:
tucatinib
Tucatinib has a moderate potential interaction with Hyperkalemia.
Tucatinib contains 60.6 mg potassium per 300 mg dose. This should be taken into consideration especially in patients with hyperkalemia or impaired kidney function who are on a controlled potassium diet.
Liver Disease
Major:
ranolazine
Ranolazine has a major potential interaction with Liver Disease.
Plasma concentrations of ranolazine increased by 30% in patients with mild (Child-Pugh Class A), and by 60% in patients with moderate (Child-Pugh B) hepatic impairment. The use of ranolazine is contraindicated in patients with clinically significant hepatic impairment.
Moderate:
tucatinib
Tucatinib has a moderate potential interaction with Liver Disease.
Tucatinib is a hepatotoxic drug. Additionally, its exposure is increased in patients with severe hepatic impairment. This is the reason why the dosage must be reduced in these patients (Child-Pugh C). Consult the manufacturers prescribing information for details on dosage modification.
Long QT Syndrome
Moderate:
ranolazine
Ranolazine has a moderate potential interaction with Long QT Syndrome.
Ranolazine prolongs the QT interval in a dose-related manner. Caution should be exercised if used in patients with long QT interval, or using other QT- prolonging drugs.
Renal Dysfunction
Moderate:
ranolazine
Ranolazine has a moderate potential interaction with Renal Dysfunction.
In patients with varying degrees of renal impairment, ranolazine plasma levels increased up to 50%, Caution is advised when used in patients with renal impairment. The pharmacokinetics of ranolazine has not been assessed in patients on dialysis.
Moderate:
tucatinib
Tucatinib has a moderate potential interaction with Renal Dysfunction.
Tucatinib contains 60.6 mg potassium per 300 mg dose. This should be taken into consideration especially in patients with hyperkalemia or impaired kidney function who are on a controlled potassium diet.
Report options
More resources
ranolazine
A total of 581 drugs are known to interact with ranolazine.
- Ranolazine is in the drug class antianginal agents.
- Ranolazine is used to treat Angina.
tucatinib
A total of 549 drugs are known to interact with tucatinib.
- Tucatinib is in the drug class HER2 inhibitors.
- Tucatinib is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.